Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03331432 · ClinicalTrials.gov registry record · NA
Effects of Dietary Supplement Tauroursodeoxycholic Acid on Vascular Function
A NA study, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT03331432: Completed NA study, sponsored by University of Missouri-Columbia.
NCT03331432 is a NA study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 8 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03331432, a NA study, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of the present study is to determine if use of dietary supplement tauroursodeoxycholic acid enhances insulin-stimulated leg blood flow and glucose disposal.
Primary Outcome
Blood flow response during insulin clamp
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Tauroursodeoxycholic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-10-28 |
| Est. Completion | 2018-02-14 |
| Phase | NA |
What the finished NCT03331432 record still lists
NCT03331432 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03331432 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03331432 about?
NCT03331432 is a clinical study titled "Effects of Dietary Supplement Tauroursodeoxycholic Acid on Vascular Function". The purpose of the present study is to determine if use of dietary supplement tauroursodeoxycholic acid enhances insulin-stimulated leg blood flow and glucose disposal.
What is the current status of trial NCT03331432?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2015-10-28. Estimated completion is 2018-02-14.
What interventions are being tested in trial NCT03331432?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Tauroursodeoxycholic acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03331432?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03331432's enrollment target sits among peer trials
8 1976th of 2000 higher than 19 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI